AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression, the AHA says.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 28, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
SGLT2 Inhibitors May Lower the Risk of Major Cardiovascular Events SGLT2 Inhibitors May Lower the Risk of Major Cardiovascular Events
SGLT2 inhibitors may lower the risk of major cardiovascular events in people with type 2 diabetes more effectively than DPP-4 inhibitors , a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
DAPA-CKD Resets eGFR Floor for Safe SGLT2 Inhibitor Use DAPA-CKD Resets eGFR Floor for Safe SGLT2 Inhibitor Use
‘ It ' s time to reduce the eGFR level for initiating an SGLT2 inhibitor to as low as 25, ’ suggests an expert.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 26, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
VERTIS CV: Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors VERTIS CV: Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors
Analyses from the trial of the sodium-glucose transporter 2 inhibitor ertugliflozin in patients with type 2 diabetes helped better define positive effects the drug had on renal function.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 25, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
THURSDAY, Sept. 24, 2020 -- For individuals with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors are associated with a reduced risk for cardiovascular events during short-term follow-up, according to a study published online Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 24, 2020 Category: Pharmaceuticals Source Type: news
Novel Type 2 Diabetes Drugs Incur High Costs in Medicare Novel Type 2 Diabetes Drugs Incur High Costs in Medicare
In Medicare Part D, beneficiaries pay 3 to 8 times more out of pocket for SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors than for older glucose-lowering agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda
The virtual 2020 meeting of the European Association for the Study of Diabetes will feature new data and insights on SGLT2 inhibitors and GLP-1 receptor agonists, technology, COVID-19, and much more.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 16, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys'DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys '
Nephrologists Jennie Lin and Leslie Gewin discuss the effects of dapagliflozin in patients with CKD. How do the DAPA-CKD findings fit with the CREDENCE data on SGLT2 inhibitors?Medscape Nephrology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 4, 2020 Category: Intensive Care Tags: Nephrology Commentary Source Type: news
SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Dr Ileana Pi ñ a asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 1, 2020 Category: Intensive Care Tags: Cardiology Commentary Source Type: news
SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news
DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 30, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
SGLT2 Inhibitors With Metformin Do Not Up Fracture Risk SGLT2 Inhibitors With Metformin Do Not Up Fracture Risk
The combination of SGLT-2 inhibitors and metformin is not associated with an increase in fracture risk among patients with type 2 diabetes, according to a meta-analysis of 25 randomized, controlled trials.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors Have a Breakout Year SGLT2 Inhibitors Have a Breakout Year
First indicated for type 2 diabetes, the benefits proven during the past year have thrust the drug class into the top tier of potential treatments for cardiac and renal disease.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 7, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported
Canadian clinicians report the rare case of a 76-year-old woman who had a sharp spike in plasma levels of rosuvastatin within days of starting the SGLT2 inhibitor.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 5, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Positive Top-line Results for Another SGLT2 Inhibitor in HF Positive Top-line Results for Another SGLT2 Inhibitor in HF
Empagliflozin reduced the risk of CV death or heart failure hospitalization in a phase 3 trial of adults with HF and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
